TX-MARY-KAY
23.6.2022 18:04:11 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in skincare innovation, recently sponsored and revealed its inaugural Mary Kay Skin Health/Skin Disease Research Grants awardees for researchers conducting groundbreaking, innovative studies in skin health and skin disease at the 2022 Society for Investigative Dermatology (SID) Annual Meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005229/en/
“As a decades-long leader in global cosmetics and skincare innovation, Mary Kay remains committed to enriching women’s lives across the world,” said Dr. Lucy Gildea, Mary Kay’s Chief Innovation Officer, Product and Science, at the event. “We also have a steadfast commitment to producing the highest quality products and conducting breakthrough skin science research. We recognize collaboration is crucial to new discoveries, and partnerships with scientific, medical, and academic communities are vital collaborations—which is why we’re thrilled to award these scientific grants.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with SID. The $25,000 grants were to be awarded to four researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2021 SID meeting, the company received applications from scientists across the country.
The four grant awardees ultimately selected were:
- Dr. Allison C. Billi , MD, Ph.D., and Assistant Professor in the Dept of Dermatology at the University of Michigan. Dr. Billi’s primary research goal is to understand “what drives photoaging.” The grant will fund research to identify targetable pathways that help prevent or potentially reverse the effects of photoaging.
- Dr. Angel S. Byrd , MD, Ph.D. and Assistant Professor at Howard University College of Medicine and Adjunct Assistant Professor at JHUSOM (Departments of Dermatology). Dr. Byrd’s work focuses on the genetic basis of melasma. This grant will fund research to help discover unknown genetic causes of melasma to design personalized treatment options.
- Dr. Mae Alexandra Carpenter , Ph.D. Trainee at Wright State University. Dr. Carpenter’s work explores how damaged DNA-containing particles are released and how they activate inflammatory pathways. Funding this research will help develop new therapeutic approaches to reduce UVB photosensitivity in autoinflammatory diseases.
- Dr. Jennifer Powers , MD and Clinical Associate Professor in the Dept of Dermatology at the University of Iowa. Dr. Powers is interested in the influence of the microbiome and the healing environment on wound healing and scar formation. Funding for this research will help understand how the immune system and microbiota interact to modify scar formation from ulcers and surgical wounds.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the Society for Investigative Dermatology—and we are thrilled to support their research.”
The sponsorship and grants revealed at SID are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn , or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005229/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartstream Smart Agents Delivers 70% Reduction in Back-Office Investigation Time, Proving the Case for Autonomous Operations26.3.2026 10:30:00 CET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that Smart Agents - its agentic AI solution for bank back-office operations is delivering measurable, transformational impact, with pilot results showing a 70% reduction in investigation time per user, per break. As the industry accelerates toward a service as software (SaS) operating model, and allowing more work to get done from software solutions, Smartstream is embracing this approach with agentic AI. The results validate a fundamental shift in how financial institutions approach exception management. In one benchmark scenario, the manual processing of 500 exceptions, typically requiring 116 hours of team effort, was reduced to just a few hours under fully autonomous operations. This eliminates swivel-chair workflows and frees up teams to focus on risk oversight, decision making, and higher-value activities. Institutions continue to struggle with back-office w
Infobip Supports Thousands of Startups and Scaleups Through Startup Tribe Programme26.3.2026 10:00:00 CET | Press release
In the first five years of the programme, Infobip has provided significant value in products and services to members, helping them build and scale customer communications worldwide Global AI-first cloud communications platform Infobip, which is celebrating its 20th anniversary this year, has supported thousands of startups and scaleups from over 120 countries in the first five years of its Startup Tribe Programme. Infobip launched its Startup Tribe Programme in May 2021 to help mission-driven startups and scaleups to build and manage their customer communications and engagement strategy and grow their business. It does this by providing access up to $60,000 in credits for Infobip’s services and its global network of advisors, investors, and accelerators. In the first five year, Infobip has provided millions in the value of products and services to its programme members. By eliminating the need to build a global communications infrastructure from the ground up, Infobip’s programme enabl
LTM Positioned as a Leader in ISG’s Provider Lens™ Evaluation for Oracle Cloud and Technology Ecosystem 202526.3.2026 09:58:00 CET | Press release
Recognition highlights LTM’s leadership across key quadrants in the United States and Europe LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in multiple quadrants in the ISG Provider Lens™ Oracle Cloud and Technology Ecosystem 2025 reports for both the United States and Europe by Information Services Group (ISG), a leading global technology research and advisory firm. The ISG Provider Lens™ study evaluates leading Oracle ecosystem service providers across critical capability areas, including: Professional Services Managed Services OCI Solutions and Capabilities LTM’s positioning as a Leader across key quadrants in both regions reflects its strong Oracle ecosystem expertise, AI-led transformation approach, and proven track record in delivering large-scale enterprise cloud modernization programs. In its 2025 study, ISG highlights that the Oracle ecosystem is undergoing a fundamental shift toward AI-native architectures, multicloud-
Bureau Veritas Strengthens Global Sustainable Finance Capabilities with Expanded Climate Bonds Approved Verifier Status26.3.2026 08:30:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), is pleased to announce the expansion of its geographical scope as an Approved Verifier under the Climate Bonds Standard and Certification Scheme. Additional offices in China, Japan, India, and France are now formally listed in the Climate Bonds Verifiers Directory. This expansion builds on Bureau Veritas’ established role since the approval of its Brazilian office in 2020, further enhancing its ability to support issuers with high-quality, independent verification services across key markets. “Our expanded presence as an Approved Verifier under the Climate Bonds Standard reinforces Bureau Veritas’ commitment to advancing credible, high‑integrity sustainable finance”, said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. “With verifier capabilities available across key markets, we continue to deliver local expertise with global assurance standards; boosting mark
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification26.3.2026 06:13:00 CET | Press release
IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). Commercial availability of the IVDR-certified assay is anticipated by early April 2026. The IVDR replaces the former In Vitro Diagnostics Directive (IVDD), introducing significantly more stringent requirements for clinical evidence, performance evaluation, traceability, and post-market surveillance. Under IVDR, in vitro diagnostic devices are classified according to risk from Class A (lowest risk) to Class D (highest risk). Class C devices, such as IdentiClone Dx IGH, are considered high-risk tests that play a critical role in disease diagnosis an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom